Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Oncology ; (12): 487-491, 2010.
Article Dans Chinois | WPRIM | ID: wpr-260369

Résumé

<p><b>OBJECTIVE</b>To evaluate the antitumor efficiency of IL-12 gene induced by RU486 regulatory system in a mouse model of orthotopically transplanted hepatoma.</p><p><b>METHODS</b>The orthotopic hepatoma model was prepared by inoculation of H22 hepatoma cells into the mouse liver. Murine interleukin-12 (IL-12) expressing plasmid pRS22 containing RU486 regulatory system was injected into mice by a hydrodynamic injection 3 days after H22 cells inoculation. Three days after hydrodynamic injection, the mice were induced with RU486 (250 µg/kg) consecutive intraperitoneal administration for 6 days. Blood samples were taken at 10 h after the first and third induction for the determination of IL-12, IFN-γ and NO. Five mice were sacrificed at 2 days after the treatment with RU486. The tumor size was measured. HE and immunohistochemical stainings were applied to evaluate the proliferative activity and angiogenesis in the tumors. The other 7 mice were kept to monitor their survival.</p><p><b>RESULTS</b>In mice receiving saline plus RU486, pRS-LacZ plus RU486, or pRS22 plus sesame oil, the liver tumors were big in size: (409.90 ± 137.03) mm(3), (271.80 ± 182.63) mm(3) and (251.00 ± 76.55) mm(3), respectively. Strong PCNA positive expression [(82.10 ± 4.62)%, (83.45 ± 2.34)% and (77.46 ± 2.99)%] and extensive microvessel density (74.58 ± 18.47, 63.60 ± 13.36 and 53.52 ± 11.74 per 400 × field), respectively, in these tumor tissues were observed after immunohistochemical staining. The survival period was shorter in these mice. In contrast, in mice treated with pRS22 plus RU486, the tumor was smaller in size. Extensive necrosis, weak PCNA proliferative activity (50.67 ± 8.09)%, and a marked paucity of microvessel density (25.38 ± 10.87) were seen. The survival of mice was obviously prolonged. Compared with the 3 control groups, a significant elevation of serum IL-12, IFN-γ and NO levels were detected in the mice treated with pRS22 plus RU486.</p><p><b>CONCLUSION</b>Expression of IL-12 gene can be effectively controlled by a RU486 regulatory system. The inducible IL-12 can delay the growth of orthotopically transplanted hepatoma and prolong the survival of mice.</p>


Sujets)
Animaux , Femelle , Humains , Souris , Carcinome hépatocellulaire , Génétique , Métabolisme , Anatomopathologie , Thérapeutique , Lignée cellulaire tumorale , Thérapie génétique , Interféron gamma , Sang , Interleukine-12 , Génétique , Métabolisme , Opéron lac , Tumeurs du foie , Génétique , Métabolisme , Anatomopathologie , Thérapeutique , Souris de lignée BALB C , Mifépristone , Pharmacologie , Transplantation tumorale , Néovascularisation pathologique , Anatomopathologie , Monoxyde d'azote , Sang , Plasmides , Génétique , Antigène nucléaire de prolifération cellulaire , Métabolisme , Répartition aléatoire
2.
Chinese Journal of Hepatology ; (12): 349-351, 2008.
Article Dans Chinois | WPRIM | ID: wpr-332237

Résumé

<p><b>OBJECTIVE</b>To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis.</p><p><b>METHODS</b>Six hepatic cirrhosis (Child-Pugh A grade, liver function compensated) patients complicated with hepatitis B virus associated glomerulonephritis diagnosed by renal biopsy, real time PCR and urinary protein tests were treated with ADV for one year in addition to a routine treatment. The dosage of ADV was 100mg daily.</p><p><b>RESULTS</b>After 3 and 6 months treatment the negative conversion rates of HBV-DNA were 33.3% and 83.3%; the negative conversion rates of HBeAg were 16.7% and 66.7%; the positive conversion rates of HBeAb were both 16.7%; the recovery rates of ALT were 83.3% and 100.0%; and the recovery rates of TBil were 66.7% and 83.3% respectively. Protein in the urine of two patients was decreased to 0.3 g/d and in three patients it was 50% of the original values. After 1 year treatment the disease subsided fully in 3 and partially in 2 patients.</p><p><b>CONCLUSION</b>Treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis using adefovir dipivoxil is effective and safe.</p>


Sujets)
Adolescent , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Adénine , Utilisations thérapeutiques , Antiviraux , Utilisations thérapeutiques , Glomérulonéphrite , Traitement médicamenteux , Virologie , Hépatite B , Traitement médicamenteux , Virus de l'hépatite B , Cirrhose du foie , Traitement médicamenteux , Virologie , Phosphonates , Utilisations thérapeutiques
SÉLECTION CITATIONS
Détails de la recherche